sanofi-aventis

• beylikler döneminde yaşanan komşu beyliğe kız vererek ilişkileri iyileştirme ya da sağlama alma olayının modern versiyonuna konu olan ilaç firması.
  (bkz: almanya ile fransanın birleşmesi)
• birlesme ile ilgili detayli haber icin:
  http://www.economist.com/…tory.cfm?story_id=2626885
  
  ve hatta siteye giremeyenler icin makalenin tamami:
  
  "after months of resistance, aventis has finally agreed to merge with sanofi. the deal follows intense pressure on both parties by the french government, which wants to create a national champion in pharmaceuticals. novartis, a swiss group that had seen itself as a possible white-knight bidder, is upset—as are some of aventis's biggest shareholders.
  
  despite the assurances from president jacques chirac at the outset of sanofi-synthélabo’s hostile bid for aventis in january, that any deal should be purely a private-sector affair, the french government has got its way. over the weekend, jean-françois dehecq, chief executive of paris-based sanofi, whose first bid in january had valued its franco-german rival at around €48 billion ($61 billion), raised its cash-and-shares offer to around €55 billion. after six hours of discussion at an emergency meeting, aventis’ board accepted the revised offer on sunday night. the new group, sanofi-aventis, will be the third-biggest drugmaker in the world, after pfizer and glaxosmithkline.
  
  in many ways, the deal is a good one for aventis’s shareholders—at around €67 a share, the revised offer is around 40% higher than the level at which the company's shares were trading before bid rumours swept the market in early january, and around 75% above their low of a year ago (see chart). moreover, many analysts reckon that—at the new price—most of the financial benefits that will emerge from the deal will go to aventis’s shareholders rather than sanofi’s. that is hardly surprising, since—in share-price terms—most big mergers are good for the prey and bad for the predator.
  
  but while some aventis shareholders are no doubt celebrating, the deal has upset others, among them novartis, a swiss drugmaker. it had entered the battle as a potential “white knight” in march, and stepped up its interest as recently as last week when it declared that it was starting formal friendly-merger negotiations with aventis. in so doing, it was listening selectively to what french politicians were saying: for example, it chose to downplay the objections of jean-pierre raffarin, the french prime minister, who claimed to be worried that an aventis/novartis tie-up might make it difficult for his country to get hold of vaccines, should it come under biological attack from terrorists. novartis also seems to have been heartened by encouraging words from germany’s economics minister, and by assurances from brussels that the european commission, rather than national governments, has jurisdiction in ruling on mergers of this size.
  
  however, no sooner had the swiss company declared its intentions last week than nicolas sarkozy, the french finance minister, called both mr dehecq and his counterpart at aventis, igor landau. he is understood to have told mr dehecq to raise his offer, mr landau to accept it, and both men to stop bad-mouthing each other. faced with such firm requests by the government (which is also a big customer of both firms), each chief executive did as he was told, and a miffed novartis backed off without bothering to submit a formal bid. mr raffarin moved swiftly to counteract criticism of the french government's intervention, insisting on monday that it “does not mean that france will be nationalistic, individualistic and egotistical, but that it will be open to projects with our european and other partners.”
  
  however, some of aventis’s shareholders were unimpressed by this french version of capitalism, which denied them the benefits of an out-and-out bid battle. the director representing the kuwait petroleum corporation, aventis’s biggest shareholder, abstained from voting on the merger. frankfurt-based union investment, a big institutional shareholder, told the wall street journal that it would vote against the deal in disgust. some are angry that mr landau is reported to be getting a golden parachute of €25m—of shareholders' money—after finally agreeing to the deal.
  
  furthermore, it will not have escaped the attention of aventis shareholders that sanofi, for all its profitability, has weaknesses as a partner. its rich earnings (it is more profitable than aventis on half the sales) are due in large part to plavix, its anti-thrombosis drug. but the plavix patent—currently due to expire in 2011—is being challenged in american courts, and there is every chance sanofi will be stripped of it. france may think it is creating a national champion, but it may turn out to be a rather sickly one."
• sanofinin önce yaptigi hostile take over bide karsi hissedarlarini önce direnmeye çagirip gazetelerde boy boy reklam vermis. sonra yeni talibi novartis olunca kiymete binmis ve sanofinin ilk teklifinden 7 milyon euro fazlasina (55 milyon euro) gelin gitmis fransiz-alman istiraki ilaç devi.
• daha önce eczacıbaşı ilacı satın alan çek firması zentiva'yı satın alarak; eczacıbaşı ilacı da satın almış olan fransız-alman ilaç firmasıdır.
• almanlarla sanofi-aventis almanya haricinde hiç bir alakası olmayan firma.aventis ile alakalı bütün yöneticileri işten uzaklaştırmışlardır zaten.
• üniversiteli bir çalışanını, yönetici asistanı olmamasına rağmen çay taşıttırdığı ve masa sildirttiği için kaybeden, kurumsallıkta sınır tanımayan, süper ilaç şirketi.
• yapılan son uygulamalar neticesinde yalnızca bu ay ve resmi olarak 320 personelini işten çıkaran ilaç firması. yılbaşından sonra neler olur allah bilir...!
  
  resmi olmayanlar ise 30 kişi civarında olacak diye tahmin ediliyor. resmi olmayan derken anlatılmak istenen şu;
  
  firma personeline bir paket tavsiye ediyor ve istifa ettikleri taktirde bu paketi hak edeceklerini vadediyor. diğer şekilde bütün kanuni haklar kendilerine teslim edilerek (resmi) işten çıkarılma işlemi gerçekleştiriliyor.
• 2009 mali yılı yönetici özetini tercüme etmiş olduğum firma.
• bünyesinde diyabet hastası sporcuları bulunduran takım.
• yakın çekime aldım kendilerini. tip 1 diyabetli olarak bisiklet takımlarını takip etmekteyim.